Affiliation:
1. Instituto de Medicina Traslacional, Trasplante y Bioingeniería (IMETTYB)‐Universidad Favaloro‐ CONICET Buenos Aires Argentina
2. Laboratorio de Ingeniería Genética y Biología Celular y Molecular, Departamento de Ciencia y Tecnología Instituto de Microbiología Básica y Aplicada, Universidad Nacional de Quilmes Bernal Provincia de Buenos Aires Argentina
Abstract
Background
Gene therapy has been proposed as a strategy to induce cardiac regeneration following acute myocardial infarction (AMI). Given that Tbx20, a transcription factor of the T‐box subfamily, stimulates cell proliferation and angiogenesis, we designed a baculovirus overexpressing
Tbx20
(Bv‐Tbx20) and evaluated its effects in cultured cardiomyocytes and in an ovine model of AMI.
Methods and Results
Cell proliferation and angiogenesis were measured in cardiomyocytes transduced with Bv‐Tbx20 or Bv‐Null (control). Subsequently, in sheep with AMI, Bv‐Tbx20 or Bv‐Null was injected in the infarct border. Cardiomyocyte cell cycle activity, angioarteriogenesis, left ventricular function, and infarct size were assessed. Cardiomyocytes transduced with BvTbx20 increased cell proliferation, cell cycle regulatory and angiogenic gene expression, and tubulogenesis. At 7 days posttreatment, sheep treated with Bv‐Tbx20 showed increased
Tbx20
, promitotic and angiogenic gene expression, decreased levels of
P21
, increased Ki67‐ (17.09±5.73 versus 7.77±7.24 cardiomyocytes/mm
2
,
P
<0.05) and PHH3 (phospho‐histone H3)‐labeled cardiomyocytes (10.10±3.51 versus 5.23±2.87 cardiomyocytes/mm
2
,
P
<0.05), and increased capillary (2302.68±353.58 versus 1694.52±211.36 capillaries/mm
2
,
P
<0.001) and arteriolar (146.95±53.14 versus 84.06±16.84 arterioles/mm
2
,
P
<0.05) densities. At 30 days, Bv‐Tbx20 decreased infarct size (9.89±1.92% versus 12.62±1.33%,
P
<0.05) and slightly improved left ventricular function. Baculoviral gene transfer‐mediated Tbx20 overexpression exerted angiogenic and cardiomyogenic effects in vitro.
Conclusions
In sheep with AMI, Bv‐Tbx20 induced angioarteriogenesis, cardiomyocyte cell cycle activity, infarct size limitation, and a slight recovery of left ventricular function, suggesting that Bv‐Tbx20 gene therapy may contribute to cardiac regeneration following AMI.
Publisher
Ovid Technologies (Wolters Kluwer Health)